337 related articles for article (PubMed ID: 16043827)
1. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
Pavletic SZ; Khouri IF; Haagenson M; King RJ; Bierman PJ; Bishop MR; Carston M; Giralt S; Molina A; Copelan EA; Ringdén O; Roy V; Ballen K; Adkins DR; McCarthy P; Weisdorf D; Montserrat E; Anasetti C
J Clin Oncol; 2005 Aug; 23(24):5788-94. PubMed ID: 16043827
[TBL] [Abstract][Full Text] [Related]
2. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
3. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
Pavletic ZS; Arrowsmith ER; Bierman PJ; Goodman SA; Vose JM; Tarantolo SR; Stein RS; Bociek G; Greer JP; Wu CD; Kollath JP; Weisenburger DD; Kessinger A; Wolff SN; Armitage JO; Bishop MR
Bone Marrow Transplant; 2000 Apr; 25(7):717-22. PubMed ID: 10745256
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.
Toze CL; Shepherd JD; Connors JM; Voss NJ; Gascoyne RD; Hogge DE; Klingemann HG; Nantel SH; Nevill TJ; Phillips GL; Reece DE; Sutherland HJ; Barnett MJ
Bone Marrow Transplant; 2000 Mar; 25(6):605-12. PubMed ID: 10734294
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
7. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.
Toze CL; Galal A; Barnett MJ; Shepherd JD; Conneally EA; Hogge DE; Nantel SH; Nevill TJ; Sutherland HJ; Connors JM; Voss NJ; Kiss TL; Messner HA; Lavoie JC; Forrest DL; Song KW; Smith CA; Lipton J
Bone Marrow Transplant; 2005 Nov; 36(9):825-30. PubMed ID: 16151430
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia.
Doney KC; Chauncey T; Appelbaum FR;
Bone Marrow Transplant; 2002 May; 29(10):817-23. PubMed ID: 12058231
[TBL] [Abstract][Full Text] [Related]
9. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
[TBL] [Abstract][Full Text] [Related]
10. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
[TBL] [Abstract][Full Text] [Related]
11. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
13. [Allogeneic transplantation in malignant lymphoma].
Stötzer OJ; Schleuning M; Ledderose G; Hiddemann W; Kolb HJ
Dtsch Med Wochenschr; 2001 Sep; 126(39):1062-9. PubMed ID: 11602913
[TBL] [Abstract][Full Text] [Related]
14. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
Cook G; Clark RE; Crawley C; Mackinnon S; Russell N; Thomson K; Pearce RM; Towlson K; Marks DI
Biol Blood Marrow Transplant; 2006 Mar; 12(3):293-300. PubMed ID: 16503498
[TBL] [Abstract][Full Text] [Related]
15. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
16. Matched unrelated donor marrow transplantation in patients with advanced acute leukemia.
Greinix HT; Reiter E; Schulenburg A; Keil F; Lechner K; Fischer G; Rosenmayr A; Leitner G; Kalhs P
Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S53-6. PubMed ID: 9916636
[TBL] [Abstract][Full Text] [Related]
17. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
[TBL] [Abstract][Full Text] [Related]
18. Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.
Schetelig J; Thiede C; Bornhäuser M; Schwerdtfeger R; Kiehl M; Beyer J; Kröger N; Hensel M; Scheffold C; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W
Ann Hematol; 2002; 81 Suppl 2():S47-8. PubMed ID: 12611075
[TBL] [Abstract][Full Text] [Related]
19. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
20. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
